Market Overview

UPDATE: Barrington Research Initiates TranS1 at Outperform on Growth Outlook

Related TSON
UPDATE: Piper Jaffray Lowers PT on TranS1 Following Updated Projections
Stocks Hitting 52-Week Lows

Barrington Research initiated coverage on TranS1 (NASDAQ: TSON) with an Outperform rating and a $4 price target.

Barrington Research said, "We estimate that the minimally invasive spinal fusion market is less than 30% of the total market and over the next few years, we expect the percentage of minimally invasive procedures to approach 60%. We estimate the potential lumbar spinal fusion market is well in excess of $1 billion. We believe TSON has the least invasive approach for the treatment of S1/L5/L4 and in our opinion, TSON will be a market leader of this segment as the company convinces the masses, doctor by doctor."

TranS1 closed at $2.42 on Friday.

Posted-In: Barrington ResearchAnalyst Color Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (TSON)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters